Inventor
NALDINI LUIGI
IT37 patents
⚠️ This page may combine multiple inventors who share the name “NALDINI LUIGI”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
OSPEDALE SAN RAFFAELE SRL
10 patentsUS11407996B2Aug 9, 2022
Gene vector
OSPEDALE SAN RAFFAELE SRL1 citations70
US10912824B2Feb 9, 2021
Vector production
OSPEDALE SAN RAFFAELE SRL4 citations69
US11753643B2Sep 12, 2023
Gene vector
OSPEDALE SAN RAFFAELE SRL0 citations62
US11957747B2Apr 16, 2024
Vector production
OSPEDALE SAN RAFFAELE SRL0 citations58
US12485187B2Dec 2, 2025
Method for improving retroviral transduction and gene editing in hematopoietic stem cells using clyclosporin H and UM171
OSPEDALE SAN RAFFAELE SRL0 citations55
US11964027B2Apr 23, 2024
Method for improving retroviral transduction and gene editing in hematopoietic stem cells using cyclosporine h (CsH)
OSPEDALE SAN RAFFAELE SRL0 citations55
US12558435B2Feb 24, 2026
Transient inhibition of p53 in gene therapy
OSPEDALE SAN RAFFAELE SRL0 citations52
US12359217B2Jul 15, 2025
Virus vector production
OSPEDALE SAN RAFFAELE SRL0 citations52
US12152240B2Nov 26, 2024
Permanent epigenetic gene silencing
OSPEDALE SAN RAFFAELE SRL0 citations51
US10617721B2Apr 14, 2020
Methods for genetic modification of stem cells
OSPEDALE SAN RAFFAELE SRL0 citations41
CELL GENESYS INC
7 patentsUS6428953B1Aug 6, 2002
Method and means for producing high titer, safe, recombinant lentivirus vectors
CELL GENESYS INC125 citations98
US6165782ADec 26, 2000
Method and means for producing high titer, safe, recombinant lentivirus vectors
CELL GENESYS INC182 citations98
US5994136ANov 30, 1999
Method and means for producing high titer, safe, recombinant lentivirus vectors
CELL GENESYS INC743 citations98
US7083981B2Aug 1, 2006
Method and means for producing high titer, safe, recombinant lentivirus vectors
CELL GENESYS INC26 citations92
US7250299B1Jul 31, 2007
Method and means for producing high titer, safe, recombinant lentivirus vectors
CELL GENESYS INC31 citations90
US6924144B2Aug 2, 2005
Method and means for producing high titer, safe, recombinant lentivirus vectors
CELL GENESYS INC8 citations73
US6797512B1Sep 28, 2004
Selection system for generating efficient packaging cells for lentiviral vectors
CELL GENESYS INC2 citations61
NALDINI LUIGI
4 patentsUS8846385B2Sep 30, 2014
Method and means for producing high titer, safe recombinant lentivirus vectors
NALDINI LUIGI31 citations95
US10000757B2Jun 19, 2018
Gene vector
NALDINI LUIGI9 citations83
US8501464B2Aug 6, 2013
Lentiviral vectors carrying synthetic bi-directional promoters and uses thereof
NALDINI LUIGI7 citations78
US8652837B2Feb 18, 2014
Method and means for producing high titer, safe, recombinant lentivirus vectors
NALDINI LUIGI4 citations71
SANGAMO BIOSCIENCES INC
3 patentsUS9937207B2Apr 10, 2018
Targeted disruption of T cell receptor genes using talens
SANGAMO BIOSCIENCES INC37 citations92
US10155011B2Dec 18, 2018
Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
SANGAMO BIOSCIENCES INC4 citations72
US10117899B2Nov 6, 2018
Delivery methods and compositions for nuclease-mediated genome engineering in hematopoietic stem cells
SANGAMO BIOSCIENCES INC2 citations72
FOND TELETHON
2 patentsSANGAMO THERAPEUTICS INC
2 patentsUS11439666B2Sep 13, 2022
Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
SANGAMO THERAPEUTICS INC0 citations62
US10918668B2Feb 16, 2021
Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
SANGAMO THERAPEUTICS INC1 citations60